Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

Refined therapy has helped to improve survival rates in rhabdoid tumors (RT). Prognosis for patients with chemoresistant, recurrent, or progressive RT remains dismal. Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly.

[1]  Thomas E. Hughes,et al.  Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia , 2018, Journal for ImmunoTherapy of Cancer.

[2]  Sandeep Kumar Dhanda,et al.  Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials , 2021, Clinical Cancer Research.

[3]  S. Bens,et al.  Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). , 2020, European journal of cancer.

[4]  M. Kool,et al.  Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus , 2019, Neuro-oncology.

[5]  S. Bens,et al.  Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT). , 2019, Neuro-oncology.

[6]  J. Gerss,et al.  Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance , 2019, Acta Neuropathologica.

[7]  D. Surdez,et al.  Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. , 2019, Cancer cell.

[8]  Steven J. M. Jones,et al.  Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration , 2019, Cell reports.

[9]  P. Kearns,et al.  Phase 1–2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia , 2019, British journal of haematology.

[10]  M. Brock,et al.  Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Teachey,et al.  A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) , 2019, Clinical Cancer Research.

[12]  M. Wildgruber,et al.  The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches , 2019, Nature Reviews Clinical Oncology.

[13]  M. Brock,et al.  Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer , 2018, International journal of cancer.

[14]  M. Frühwald,et al.  Emerging therapeutic targets for the treatment of malignant rhabdoid tumors , 2018, Expert opinion on therapeutic targets.

[15]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[16]  Rare Tumors in Kids May Respond to Tazemetostat. , 2018, Cancer discovery.

[17]  N. André,et al.  Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report , 2017, Front. Pharmacol..

[18]  D. Eslin,et al.  Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse. , 2017, Journal of pediatric hematology/oncology.

[19]  K. Oetjen,et al.  Immunological effects of hypomethylating agents , 2017, Expert review of hematology.

[20]  N. Penel,et al.  irRECIST and iRECIST: the devil is in the details. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Jason E. Farrar,et al.  A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML , 2017, bioRxiv.

[22]  M. Fischer,et al.  A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors , 2017, Clinical Cancer Research.

[23]  M. Beckmann,et al.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2017, Cell.

[24]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[25]  A. King,et al.  Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database , 2017, Cancer.

[26]  L. Schwartz,et al.  High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy , 2016, Journal of Hematology & Oncology.

[27]  M. Prados,et al.  Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. , 2016, Neuro-oncology.

[28]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[29]  Mei Lu,et al.  Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. , 2016, Cancer cell.

[30]  C. Roberts,et al.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. , 2016, Neuro-oncology.

[31]  R. Siebert,et al.  Improved 6‐year overall survival in AT/RT – results of the registry study Rhabdoid 2007 , 2016, Cancer medicine.

[32]  W. Han,et al.  DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire , 2016, Oncotarget.

[33]  Steven J. M. Jones,et al.  Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. , 2016, Cancer cell.

[34]  Roland Eils,et al.  Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. , 2016, Cancer cell.

[35]  P. Cabrales,et al.  Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization , 2016, Case Reports in Oncology.

[36]  A. Koch,et al.  Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report , 2016, Child's Nervous System.

[37]  D. Matei,et al.  Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study , 2015, PloS one.

[38]  Xin Hu,et al.  Epigenetic synergy between decitabine and platinum derivatives , 2015, Clinical Epigenetics.

[39]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[40]  L. Diller,et al.  A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.

[41]  R. Day,et al.  Episensitization: Defying Time’s Arrow , 2015, Front. Oncol..

[42]  Martin Bendszus,et al.  Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.

[43]  C. Wetmore,et al.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. , 2015, Neuro-oncology.

[44]  M. Massimino,et al.  A case of relapsing spinal atypical teratoid/rhabdoid tumor (AT/RT) responding to vinorelbine, cyclophosphamide, and celecoxib , 2015, Child's Nervous System.

[45]  Gary D Bader,et al.  Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. , 2015, The Lancet. Oncology.

[46]  S. Fulda,et al.  RIST: A potent new combination therapy for glioblastoma , 2015, International journal of cancer.

[47]  T. Athanasiou,et al.  Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature , 2015, Journal of Neuro-Oncology.

[48]  H. Kantarjian,et al.  Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.

[49]  M. Kool,et al.  Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1 , 2014, International journal of cancer.

[50]  R. Siebert,et al.  SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis , 2014, Acta Neuropathologica.

[51]  D. Matei,et al.  Decitabine reactivated pathways in platinum resistant ovarian cancer , 2014, Oncotarget.

[52]  B. Geoerger,et al.  Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. , 2013, Neuro-oncology.

[53]  R. Garzon,et al.  Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults , 2013, British journal of haematology.

[54]  V. Marquez,et al.  Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. , 2013, Neuro-oncology.

[55]  D. Krishnadas,et al.  Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma , 2013, Pediatrics.

[56]  L. Garraway,et al.  Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors , 2012, Pediatric blood & cancer.

[57]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[59]  D. Johnston,et al.  Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. , 2012, European journal of cancer.

[60]  R. Vibhakar,et al.  Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells , 2012, Journal of Neuro-Oncology.

[61]  D. Zagzag,et al.  Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. , 2011, Cancer research.

[62]  J. Biegel,et al.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors , 2011, Pediatric blood & cancer.

[63]  D. Neuberg,et al.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study , 2010, Pediatric blood & cancer.

[64]  R. Siebert,et al.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.

[65]  R. Barr,et al.  Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous System: A Meta-Analysis of Observational Studies , 2009, Journal of pediatric hematology/oncology.

[66]  J. Biegel,et al.  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[68]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[70]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[71]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[72]  G. Rivard,et al.  Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. , 1983, Cancer research.